Antiplatelet Secondary Prevention International Randomised trial after INtracerebral haemorrhaGe

Lead PI: Professor Graeme J. Hankey and Professor Craig S. Anderson 

Participating Australian and New Zealand Sites:Austin Health (VIC), Ballarat Base Hospital (VIC)Bankstown Hospital (NSW)Fiona Stanley Hospital (WA), John Hunter Hospital (NSW), Liverpool Hospital (NSW), Royal Adelaide Hospital (SA), Royal Brisbane & Womens Hospital (QLD), Royal Darwin Hospital (NT)Royal Melbourne Hospital (VIC), Royal Prince Alfred Hospital (NSW), Shoalhaven Hospital (NSW), Sir Charles Gairdner Hospital (WA)Guanghan People’s Hospital, Huadong Hospital, Huashan Hospital, Shanghai Fengcheng Hospital

Status: ASTN Endorsed, Site selection

No. of Patients Currently Recruited: 2                             No. of Patients Required: pilot phase 120,
                                                                                              main phase 4148 worldwide

Aim: To determine if antiplatelet monotherapy is of overall net benefit in reducing the incidence of serious vascular events compared to avoiding antiplatelet therapy for adults with a history of spontaneous ICH. 

Design: Randomised, open-label, blinding outcome (PROBE), parallel-group clinical trial. 

Intervention: Start open-label antiplatelet monotherapy (aspirin or clopidogrel – your choice) OR Avoid antiplatelet therapy (no placebo is involved). 

Outcome – primary: Composite of stroke (ischaemic and haemorrhagic), myocardial infarction and death due to vascular causes 

Trial URL:


Related Posts